Get the Stockscreener App
77.09
16.71%
11.04
After Hours:
76.15
-0.94
-1.22%
Cytokinetics Inc stock is traded at $77.09, with a volume of 18.09M.
It is up +16.71% in the last 24 hours and up +15.53% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$66.05
Open:
$74.685
24h Volume:
18.09M
Relative Volume:
8.47
Market Cap:
$9.58B
Revenue:
$88.04M
Net Income/Loss:
$-784.96M
P/E Ratio:
-11.80
EPS:
-6.5335
Net Cash Flow:
$-534.82M
1W Performance:
+27.02%
1M Performance:
+15.53%
6M Performance:
+30.24%
1Y Performance:
+110.23%
1-Day Range:
$73.06
$80.20
1-Week Range:
$58.65
$80.20
52-Week Range:
$29.31
$80.20
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
77.09 | 8.21B | 88.04M | -784.96M | -534.82M | -6.5335 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Wells Fargo | Overweight |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-18-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Insider Sell Alert: Andrew Callos Sells Shares of Cytokinetics I - GuruFocus
Cytokinetics Shares Phase 3 ACACIA-HCM Win: Aficamten Hits Dual Endpoints in nHCM Trial - Yahoo Finance
Cytokinetics EVP Malik sells $270,795 in company stock - Investing.com
Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance Singapore
Cytokinetics (CYTK) Q1 2026 Earnings Transcript - The Globe and Mail
Cytokinetics announces proposed public offering of common stock - marketscreener.com
Cytokinetics (CYTK) EVP executes 3,500-share option exercise and sale - Stock Titan
Cytokinetics metrics satisfy in nHCM phase III - BioWorld News
Cytokinetics Incoffers common stock with aggregate public offering price of $650 millionSEC filing - marketscreener.com
Earnings call transcript: Cytokinetics Q1 2026 results show revenue surge - Investing.com
Cytokinetics plans $650 million common stock offering - Investing.com
Earnings Flash (CYTK) Cytokinetics, Incorporated Reports Q1 Revenue $19.4M, vs. FactSet Est of $8.5M - marketscreener.com
Cytokinetics (NASDAQ: CYTK) seeks $650M via common stock shelf offering - Stock Titan
[144] CYTOKINETICS INC SEC Filing - Stock Titan
Cytokinetics: Q1 Earnings Snapshot - marketscreener.com
Insider to sell 23,906 Common shares — Cytokinetics (NASDAQ: CYTK) - Stock Titan
Cytokinetics plans $650 million common stock offering By Investing.com - Investing.com Canada
Director Wierenga trims Cytokinetics (CYTK) stake via option exercise and sale - Stock Titan
How This Biotech Scored 'A Clear Win' Where Bristol Myers Failed - Investor's Business Daily
Cytokinetics (CYTK) CFO trims stake with 23,906-share sale - Stock Titan
Biotech Cytokinetics seeks $650M stock sale, plus 15% option - Stock Titan
Cytokinetics stock adds more than $1 billion of valuation in a single day — Here's why - The Business Journals
Cytokinetics Announces Proposed Public Offering of Common Stock - marketscreener.com
[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan
Cytokinetics (NASDAQ: CYTK) details MYQORZO rollout and $1.1B cash - Stock Titan
Cytokinetics (CYTK) EVP Callos exercises options and sells 11,333 shares - Stock Titan
[10-Q] CYTOKINETICS INC Quarterly Earnings Report - Stock Titan
MYQORZO launch drives revenue jump as Cytokinetics (NASDAQ: CYTK) posts Q1 2026 loss - Stock Titan
680 patients prescribed MYQORZO in Q1; EU approval follows - Stock Titan
BofA raises Cytokinetics price target on ACACIA trial results - Investing.com
Cytokinetics earnings on deck as trial results loom large By Investing.com - Investing.com Australia
Cytokinetics earnings on deck as trial results loom large - Investing.com
CYTK Stock Jumps As Traders Brace For ACACIA Data - StocksToTrade
Cytokinetics stock hits 52-week high after ACACIA-HCM trial - Yahoo Finance
Cytokinetics Stock Rallies After Pivotal Heart Disease Study Hits Dual Primary Endpoints - Benzinga
This Is Why Cytokinetics Stock (CYTK) Soared Today - TipRanks
CYTK Jumps As $95 Target, Trial Catalyst Ignite Trading - StocksToTrade
Cytokinetics stock hits 52-week high at 74.35 USD - Investing.com
Cytokinetics heart drug scores in closely watched trial - BioPharma Dive
Cytokinetics surges 28% on promising heart drug results - Rolling Out
Cytokinetics’ aficamten meets trial goals in heart disease study By Investing.com - Investing.com Canada
Cytokinetics heart disease drug meets main goals in late-stage study - TradingView
Cytokinetics stock surges on positive trial results By Investing.com - Investing.com Canada
Cytokinetics stock surges on positive trial results - Investing.com
CYTK: Aficamten met all primary and key secondary endpoints in non-obstructive HCM Phase 3 trial - TradingView
Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy - Cytokinetics
In a heart disease with no approved drugs, aficamten hits Phase 3 goals - Stock Titan
Cytokinetics succeeds where Bristol Myers failed in heart muscle disease - Endpoints News
Heart drug trial readout from Cytokinetics is due Tuesday morning - Stock Titan
Cytokinetics Insider Sold Shares Worth $1,030,705, According to a Recent SEC Filing - marketscreener.com
Cytokinetics to report ACACIA-HCM trial results Tuesday - Investing.com
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):